What we do

pulmon cancer

FibroStatin is advancing a groundbreaking development to fight drug resistant lung cancer

The Company’s developments and treatment candidates derive from its proprietary GPBP technology. GPBP is a unique, patent-protected, extracellular kinase target that regulates the organization of the collagen IV network stabilizing mesenchymal tumor phenotype from which drug resistance and invasiveness emerge. More specifically, the collagen IV network stabilizes tumor cells that underwent an epithelial-to-mesenchymal transition (EMT), which confers chemo resistance and imparts in tumor cells migratory and invasive properties. This transition is recognized as a requirement for metastatic cancer and drug resistance to emerge. FibroStatin’s science and developments have application to other types of cancers including breast cancer.

FibroStatin has used rational drug design to identify FST12, a First-in-Class small molecule inhibitor of GPBP that targets the high molecular weight oligomers of GPBP that appear during EMT and other pathological conditions. FST12 significantly reduces tumor growth and metastasis in numerous animal models. Also, initial dose ranging toxicity studies show a substantial safety margin.

FibroStatin’s GPBP technology is also being applied to idiopathic pulmonary fibrosis

The epithelial-to-mesenchymal transition also mediates organ fibrosis, the pathological state of excess fibrous formation that develops in many diseases including pulmonary fibrosis, advanced kidney disease, rheumatoid arthritis, and diabetes. The Company has developed GPBP specific monoclonal antibodies that target the high molecular weight oligomers of GPBP that are active during EMT. One of these designated FSM26 significantly reduces tissue fibrosis and extends animal survival in animal models of IPF.